We will help you navigate through the challenges of reimbursement and funding for medical devices and in-vitro diagnostics in Europe

MTRC is a provider of on-demand and off-the-shelf European reimbursement analysis and strategy for industry and investment companies

News and blog posts

Stay up-to-date about developments of reimbursement systems in Europe

06 Dec 2017
The Institute for Quality and Efficiency in Health Care (IQWiG), in agreement with the relevant manufacturers' associations, has drafted a model contract to regulate the conditions under which information provided by manufacturers for the evaluation of medical devices is used by IQWiG and made available to third parties.


Jan 2018

The program will cover the period of 2018-2025 and will focus on improvement of provision of health care services, introduction of innovations and other aspects of health care system. Overall budget of the program is 4.7 bln. euros. The program can create a window of opportunity for financing of innovative equipment and devices in Russia.


Jan 2018

A 104-page reimbursement report covers percutaneous, thoracoscopic and open in adjunction to heart surgery ablations in hospital settings. Radiofrequency, cryo and microwave ablation sources were considered. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.


Jan 2018

The Clinical Coding and Schedule Development Group develops and maintains procedural and diagnostics nomenclature for private payers in England. In November new codes for reconstruction of breast, open adnexectomy, transoral laser microsurgery and surgical correction of hallux valgus were added to the CCSD Schedule.


Jan 2018

The Department of Home Affairs (EDI) in Switzerland decided upon the coverage with evidence development (CED) of two types of positron emission tomography as well as stereotactic radiotherapy (photons) of exudative age-related macular degeneration. The status is given to contested medical services for a specific period which is extended until evidence is complete.

About us

We are a group of enthusiasts who are passionate about the areas of health policy, evidence generation, reimbursement and funding for medical technologies. We have turned our passion into a career. More specifically, we develop insights which help our customers optimize their business decisions

Our company is based in Stockholm, Sweden

The founder of company is Oleg Borisenko, one of the leading experts on European market access for medical devices. With more than 11 years of experience in the field, Oleg has led several hundred of projects. These include reimbursement analyses and strategies, value dossiers, health economic models and evidence generation strategies

Our team consists of eight clinical coders and market analysts, including five medical doctors and one pharmacist. Three of our members have PhD degrees in different areas of clinical and public health science

Our unique proposition is Pan-European reimbursement mapping and strategy projects for the Med Tech and IVD industries. To match the requirements and budget of our various customers, we approach their needs differently: from low-cost off-the-shelf reimbursement reports for dozens of medical technologies to full scale reimbursement and evidence generation projects

We provide analyses for 14 European countries

Check out our database of the off-the-shelf reimbursement reports for medical technologies in 11 European countries

Released reports:

  • Transcatheter aortic valve implantation (TAVI) 
  • Eight minimally invasive and transcatheter mitral valve repair and replacement technologies
  • Group of peripheral vascular arterial interventions (angioplasty, angioplasty using drug-eluting balloon, stenting using bare metal and drug-eluting stents, atherectomy, periperal IVUS)
  • Robotic surgery interventions
  • Peripheral venous interventions for deep vein thrombosis and venous insufficiency
  • Coronary percutaneous revascularization (angioplasty using plain and drug-coated balloon, bare metal and drug-eluting stents, mechanical thrombectomy, percutaneous atherectomy)

Reports scheduled for release in December 2017:

  • Coronary percutaneous imaging procedures (angiography, IVUS, FFR, OCT)
  • Mechanical thrombectomy for stroke
  • Ablation of heart tissue for atrial fibrillation
  • Procedures on spine for intervertebral disc prolapse, vertebra fracture
  • Interventional procedure for gastro-esophageal reflux disease